Major depressive disorder, often referred to as major depression, is a heterogenous condition with complex and diverse neurobiological etiologies. Depression is characterized by a triad of symptoms: low or depressed mood, anhedonia and low energy or fatigue. Approximately 15% of the population in developed countries has been affected by depression in their lifetime and the chance of developing depression is twice as high in women. 40-50% of depressive causes are inheritable (genes as yet unidentified) and the remaining 50-60% of causes are caused by environmental stressors.
Depression Research Product Areas
Pathogenesis of Depression
Traditionally, depression has been described as a disease of decreased monoamine function within the brain (also known as the monoamine hypothesis). Brain areas specifically involved are thought to include the hippocampus, prefrontal and cingulate cortex, and the amygdala. In addition the dopaminergic reward pathway, in particular the nucleus accumbens, and the hypothalamus may also be involved, and have been identified due to the symptoms of anhedonia, and abnormalities in sleep, appetite and circadian rhythms respectively, which are prevalent in depressed patients.
Depression may also be caused by an enhancement of biological stress-response mechanisms, especially the hypothalamic-pituitary-adrenal (HPA) axis, is a common feature of depression, which is manifested by increased corticotrophin releasing factor (CRF) expression in the hypothalamus and cerebrospinal fluid (CSF).
The main obstacle for depression research has been the lack of animal models for some depressive symptoms, such as guilt and suicidal ideology. This has hampered efforts to fully understand the disease and it remains an area of intense research.
Current pharmacological interventions for depression focus on potentiation of the monoamine system. Tricyclic antidepressants act by inhibiting serotonin and/or noradrenalin uptake and monoamine oxidase (MAO) inhibitors reduce the enzymatic breakdown of serotonin, noradrenalin and dopamine. Novel pharmacological targets focusing on non-monoamine systems, such as CRF antagonists, GR antagonists, cytokines, melatonin receptor agonists, TrkB agonists, histone deacetylase (HDAC) inhibitors and κ-opioid receptor antagonists, are currently being developed.
Find multiple products by catalog number
July 8 - 12, 2017